NCT01238796

A Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

A Phase 1 Open-Label Study to Evaluate the Effect of Renal Function on the Biological Activity of Telavancin

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 45 (actual)
• Sponsor: Cumberland Pharmaceuticals · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Accepted

Summary

The purpose of this study is to evaluate the effect of renal function on the biological activity of telavancin using blood samples obtained from subjects with normal renal function, severe renal impairment, and end stage renal disease.

Conditions

• Kidney Diseases
• End Stage Renal Disease

Interventions

Type	Name	Description
DRUG	telavancin	Intravenous

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-02-01
• Completion: 2011-02-01
• First posted: 2010-11-11
• Last updated: 2019-01-15

Locations

4 sites across 1 country: United States